Ionis Pharmaceuticals begins donidalorsen phase 3 trial in hereditary angioedema

Ionis Pharmaceuticals, a US-based developer of RNA-targeted therapies, has launched the OASIS-HAE phase 3 clinical trial for donidalorsen (formerly IONIS-PKK-LRx) in patients having hereditary angioedema ... Read More